Iran Guards said they fired missiles at Israel and US forces in bases in Kuwait, Jordan and Bahrain; crude oil prices fall sharply in early trading Trump’s rehashed 15-point Iran plan unlikely to appease Tehran Disruptions to international fertiliser supplies caused by the closing of the strait of Hormuz will cause food scarcity and high prices, the World Trade Organisation’s deputy director gener...
Iran Guards said they fired missiles at Israel and US forces in bases in Kuwait, Jordan and Bahrain; crude oil prices fall sharply in early trading Trump’s rehashed 15-point Iran plan unlikely to appease Tehran Disruptions to international fertiliser supplies caused by the closing of the strait of Hormuz will cause food scarcity and high prices, the World Trade Organisation’s deputy director general, Jean-Marie Paugam , told Agence France-Press. A third of the world’s fertilisers normally transit the strait , which has been virtually closed by Iran since the start of the war. Continue reading...
Sundry Photography Merck & Co. ( MRK ) is close to an approximately $6 billion all-cash deal to buy US biotech firm Terns Pharmaceuticals ( TERN ) as it seeks to boost its drug pipeline ahead of cancer treatment Keytruda’s patent expiry, the Financial Times reported. The talks are at an advanced stage and could be finalized in the coming days, the FT reported, citing people it didn’t identify. Ter...
Sundry Photography Merck & Co. ( MRK ) is close to an approximately $6 billion all-cash deal to buy US biotech firm Terns Pharmaceuticals ( TERN ) as it seeks to boost its drug pipeline ahead of cancer treatment Keytruda’s patent expiry, the Financial Times reported. The talks are at an advanced stage and could be finalized in the coming days, the FT reported, citing people it didn’t identify. Terns ( TERN ) had a $5.4 billion market capitalization as of Tuesday’s close. Merck and Terns didn’t immediately respond to requests for comment from the FT. Following the news, shares of Terns Pharma, which focuses on developing treatments for chronic myeloid leukemia, rose about 10% in after-hours trading. Merck ( MRK ) has been pursuing deals to strengthen its pipeline, with CEO Rob Davis spearheading a strategy to diversify the company's portfolio ahead of the 2028 patent expiration for its blockbuster cancer drug, Keytruda. More on Merck, Terns Pharmaceuticals Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Merck: Why Investors Should Remain Bullish Despite Patent Risks U.S. starts seeking drugmakers’ views in turning Trump's pricing deals into law Merck granted FDA approval to expand Bravecto label for tick species in dogs